Enfuvirtid Asetat (T-20)
takma ad:Fuzeon
Sekans:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
CAS Numarası. : 159519-65-0
Moleküler formül : C204H301N51O64
Moleküler ağırlık : 4492
Saflık (HPLC) : 98.0%dk.
Dış görünüş : Beyazdan kirli beyaza amorf katı
Tek Kirlilik (HPLC) : 0.5%maksimum
Amino Asit Bileşimi : ± teorik
Peptit İçeriği (N%) : ≥80.0
Su içeriği (karl Fischer) : ≤8.0%
TrifloroAsetat İçeriği(HPIC) : ≤12.0%
HANIM (ESI) : Tutarlı
Kütle dengesi : 95.0~105.0%
Seviye : İlaç Derecesi
Depolamak: Kapalı, aşağıda 2 ~ 8 ℃ koruma
kullanım : HIV/AIDS hastaları için tedavi seçeneği.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (HAN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
